The MHRA is inviting members of the public to provide their views on proposed changes to the regulatory framework for medical devices.
Similar Posts
Field Safety Notices: 24 to 28 November 2025
List of Field Safety Notices from 24 to 28 November 2025.
Class 4 Medicines Defect Notification: Fexofenadine Hydrochloride 120mg film-coated tablets, Chanelle Medical Unlimited Company, EL(25)A/41
Chanelle Medical Unlimited Company has informed the MHRA of an error with the European Article Number (EAN) / Global Trade Item Number (GTIN) barcode on certain batches of Fexofenadine Hydrochloride 120mg film-coated tablets, distributed by Healthcare Pharma Limited.
Corporate report: MHRA Corporate Plan: 2023 to 2026 and Business Plan: 2025 to 2026
These reports outline the MHRA’s Corporate and Business Plans, detailing the agency’s strategic direction over the next three years.
Cosmetic Breast Augmentation Risk Awareness Tool
New Cosmetic Breast Augmentation Risk Awareness Tool for patients to use when considering cosmetic breast implant surgery.
Transparency data: Medicines and Healthcare products Regulatory Agency spending over £25,000: 2025 to 2026
Information on Medicines and Healthcare products Regulatory Agency spending over £25,000.
Professor Henrietta Hughes: Putting Patient Safety at the Heart of Regulatory Innovation
Professor Henrietta Hughes reflects on how MHRA strategy must prioritise patient safety via listening to lived experiences, fostering collaboration & innovation.
